Effect of ipratropium bromide in bronchial asthma.

V. Taskar, L. Mirchandani, A. A. Mahashur, R. R. Sharma, V. P. Kolhatkar

Research output: Contribution to journalArticle

Abstract

The effect of inhalation of ipratropium bromide was evaluated in 20 patients with bronchial asthma. It was observed that there was no significant improvement in the forced vital capacity and the forced expired volume in one second, while there was significant improvement in the peak expiratory flow rate (PEFR) measured at 9 pm, after inhalation of 2 puffs of ipratropium bromide aerosol (0.02mg/puff) three to four times a day for 2 weeks. Since PEFR is a measure of large airway function and cholinergic mechanisms are primarily involved for airflow obstruction at large airways, improvement in PEFR by ipratropium bromide highlights its role as a useful bronchodilator in patients in whom vagal reflexes are responsible for the provocation of bronchoconstriction.

Original languageEnglish (US)
Pages (from-to)124-126
Number of pages3
JournalJournal of postgraduate medicine
Volume38
Issue number3
StatePublished - Jan 1 1992
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of ipratropium bromide in bronchial asthma.'. Together they form a unique fingerprint.

  • Cite this

    Taskar, V., Mirchandani, L., Mahashur, A. A., Sharma, R. R., & Kolhatkar, V. P. (1992). Effect of ipratropium bromide in bronchial asthma. Journal of postgraduate medicine, 38(3), 124-126.